GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development

 
• By Joseph Haas

Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

Transfer
An Arrowhead-discovered HBV candidate is going from J&J to GSK • Source: Shutterstock

More from Deals

More from Business